Response to comments regarding article, “Wnt5a inhibited human trophoblast cell line HTR8/SVneo invasion: implications for early placentation and preeclampsia”

References

• Chen Y, Zhang Y, Deng Q, et al. Wnt5a inhibited human trophoblast cell line HTR8/SVneo invasion: implications for early placentation and preeclampsia. J Matern Fetal Neonatal Med 2016. [Epub ahead of print]. doi: 10.3109/14767058.2016.1138102
   Web of Science ®Google Scholar
• Nishita M, Enomoto M, Yamagata K, Minami Y. Cell/tissue-tropic functions of Wnt5a signaling in normal and cancer cells. Trends Cell Biol 2010;20:346–54
   PubMed Web of Science ®Google Scholar
• McDonald SL, Silver A. The opposing roles of Wnt-5a in cancer. Br J Cancer 2009;101:209–14
   PubMed Web of Science ®Google Scholar
• Ford CE, Punnia-Moorthy G, Henry CE, et al. The non-canonical Wnt ligand, Wnt5a, is upregulated and associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Gynecol Oncol 2014;134:338–45
   PubMed Web of Science ®Google Scholar
• McCall KD, Harii N, Lewis CJ, et al. High basal levels of functional toll-like receptor 3 (TLR3) and noncanonical Wnt5a are expressed in papillary thyroid cancer and are coordinately decreased by phenylmethimazole together with cell proliferation and migration. Endocrinology 2007;148:4226–37
   PubMed Web of Science ®Google Scholar
• Lejeune S, Huguet EL, Hamby A, et al. Wnt5a cloning, expression, and up-regulation in human primary breast cancers. Clin Cancer Res 1995;1:215–22
   PubMed Web of Science ®Google Scholar
• Roarty K, Baxley SE, Crowley MR, et al. Loss of TGF-beta or Wnt5a results in an increase in Wnt/beta-catenin activity and redirects mammary tumour phenotype. Breast Cancer Res 2009;11:R19
   PubMed Web of Science ®Google Scholar
• Syed Khaja AS, Helczynski L, Edsjö A, et al. Elevated level of Wnt5a protein in localized prostate cancer tissue is associated with better outcome. PLoS One 2011;6:e26539
   PubMed Web of Science ®Google Scholar
• Tseng JC, Lin CY, Su LC, et al. CAPE suppresses migration and invasion of prostate cancer cells via activation of non-canonical Wnt signaling. Oncotarget 2016. [Epub ahead of print]. doi: 10.18632/oncotarget.9380
   Web of Science ®Google Scholar
• Kremenevskaja N, von Wasielewski R, Rao AS, et al. Wnt-5a has tumor suppressor activity in thyroid carcinoma. Oncogene 2005;24:2144–54
   PubMed Web of Science ®Google Scholar
• Bitler BG, Nicodemus JP, Li H, et al. Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence. Cancer Res 2011;71:6184–94
   PubMed Web of Science ®Google Scholar
• Lyros O, Nie L, Moore T, et al. Dysregulation of WNT5A/ROR2 signaling characterizes the progression of Barrett's-associated esophageal adenocarcinoma. Mol Cancer Res 2016;14:647–59
   PubMed Web of Science ®Google Scholar
• Dejmek J, Dejmek A, Säfholm A, et al. Wnt-5a protein expression in primary dukes B colon cancers identifies a subgroup of patients with good prognosis. Cancer Res 2005;65:9142–6
   PubMed Web of Science ®Google Scholar
• Soundararajan R, Rao AJ. Trophoblast 'pseudo-tumorigenesis': significance and contributory factors. Reprod Biol Endocrinol 2004;2:15
   PubMedGoogle Scholar
• Fafet P, Rebouissou C, Maudelonde T, Vignais ML. Opposite effects of transforming growth factor-beta activation and rho-associated kinase inhibition on human trophoblast migration in a reconstituted placental-endometrial coculture system. Endocrinology 2008;149:4475–85
   PubMed Web of Science ®Google Scholar
• Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004;20:781–810
   PubMed Web of Science ®Google Scholar
• Topol L, Jiang X, Choi H, et al. Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation. J Cell Biol 2003;162:899–908
   PubMed Web of Science ®Google Scholar
• Ying J, Li H, Yu J, et al. WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/beta-catenin signaling, and is frequently methylated in colorectal cancer. Clin Cancer Res 2008;14:55–61
   PubMed Web of Science ®Google Scholar
• Yu XM, Wang L, Li JF, et al. Wnt5a inhibits hypoxia-induced pulmonary arterial smooth muscle cell proliferation by downregulation of β-catenin. Am J Physiol Lung Cell Mol Physiol 2013;304:L103–11
   Google Scholar
• Mikels AJ, Nusse R. Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol 2006;4:e115
   PubMed Web of Science ®Google Scholar
• Borcherding N, Kusner D, Kolb R, et al. Paracrine WNT5A signaling inhibits expansion of tumor-initiating cells. Cancer Res 2015;75:1972–82
   PubMed Web of Science ®Google Scholar
• Qi X, Okinaka Y, Nishita M, Minami Y. Essential role of Wnt5a-Ror1/Ror2 signaling in metanephric mesenchyme and ureteric bud formation. Genes Cells 2016;21:325–34
   PubMed Web of Science ®Google Scholar
• Dejmek J, Säfholm A, Kamp Nielsen C, et al. Wnt-5a/Ca2+-induced NFAT activity is counteracted by Wnt-5a/Yes-Cdc42-casein kinase 1alpha signaling in human mammary epithelial cells. Mol Cell Biol 2006;26:6024–36
   PubMed Web of Science ®Google Scholar
• Roshan Moniri M, Young A, Reinheimer K, et al. Dynamic assessment of cell viability, proliferation and migration using real time cell analyzer system (RTCA). Cytotechnology 2015;67:379–86
   PubMed Web of Science ®Google Scholar
• Lin CH, Chang CY, Lee KR, et al. Flavones inhibit breast cancer proliferation through the Akt/FOXO3a signaling pathway. BMC Cancer 2015;15:958
   PubMed Web of Science ®Google Scholar
• Uraki S, Sugimoto K, Shiraki K, et al. Human β-defensin-3 inhibits migration of colon cancer cells via downregulation of metastasis-associated 1family, member 2 expression. Int J Oncol 2014;45:1059–64
   PubMed Web of Science ®Google Scholar
• Peng S, Zhang J, Chen J, Wang H. Effects of Wnt5a protein on proliferation and apoptosis in JAR choriocarcinoma cells. Mol Med Rep 2011;4:99–104
   PubMed Web of Science ®Google Scholar